ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2025
Obesity-related drug-metabolizing enzyme expression alterations in the human liver.
Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tissue-derived extracellular vesicles-mediated delivery of a hepatic enzyme living panorama (HELP) for treating multifactorial liver diseases.Journal of nanobiotechnology · 2026Article
- Link between physical activity, nutrition, and antimicrobial pharmacokinetics and therapeutic efficacy: Implications for resistance management.SAGE open medicine · 2026Review
- Does Genetic Variation in Detoxification Capacity Influence Hepatic Biomarker Responses to a Liver Support Supplementation Regimen?International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveImplications of obesity extend beyond the association with various health conditions, impacting physiological changes that affect the liver and the activity of metabolizing enzymes. Given the prevalence of obesity and the risk for drug-drug interactions owing to the comorbidity burden, the current drug dosage recommendations may need reevaluation for patients with obesity. This study evaluated the implications of obesity on the gene expression of hepatic drug-metabolizing enzymes. As drug clearance is an essential pharmacokinetic parameter for maintaining drug dosing regimens, investigating alterations in metabolizing enzymes expression is a critical step.
methodsHuman liver samples were collected post-mortem from 32 individuals and classified into the control (18.5 ≤ BMI <25 kg/m
resultsOur studies revealed several potential physiologically relevant differences, but the statistical significance was reached only for ALDH3B1, PTGS1, and CEL (all being up-regulated in the study group).
conclusionsThe study adds to our understanding of the mechanisms of pharmacokinetic changes in overweight and obesity. The findings require further exploration on the protein level, through proteomic and functional studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.